GlassScriptPhysician profile
Nichole Smith
NPI 1053444679
$2,869.83
in general payments reported to CMS, 2019-2025
31 companies · $983 in 2025
The $983 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $440 · 2023: $426 · 2024: $262 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $622.40 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $380.96 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $352.24 | 2021-2025 | |
| Abbott Laboratories | $221.05 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $180.00 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $132.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $117.32 | 2021 | |
| Glaxosmithkline, LLC. | $114.47 | 2022-2025 | Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.88 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $68.06 | 2021-2024 | Veozah |
| Amneal Pharmaceuticals LLC | $65.67 | 2021-2025 | Unithroid |
| Pfizer INC. | $51.08 | 2024-2025 | |
| Corium, LLC | $49.11 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $47.64 | 2021-2023 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $44.77 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $34.53 | 2023-2025 | Jatenzo |
| Medtronic, INC. | $34.49 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.95 | 2021 | |
| Organon LLC | $23.93 | 2022 | |
| Agios Pharmaceuticals, INC. | $23.82 | 2025 | Pyrukynd |
| Itamar Medical INC | $23.33 | 2023 | Watchpatone |
| Biohaven Pharmaceuticals, INC. | $21.65 | 2021 | |
| Halozyme INC | $21.61 | 2023 | |
| Axsome Therapeutics, INC. | $20.91 | 2025 | Sunosi |
| Globus Medical, INC. | $19.91 | 2025 | Senza |
| Antares Pharma, INC. | $17.25 | 2025 | Xyosted |
| Merck Sharp & Dohme LLC | $17.13 | 2025 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $16.10 | 2023 | Trintellix |
| Biodelivery Sciences International, INC. | $15.56 | 2021 | |
| Genentech USA, INC. | $13.07 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.